# Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders

> **NCT00624325** · PHASE2,PHASE3 · COMPLETED · sponsor: **Foundation for Liver Research** · enrollment: 30 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** interferon alfa-2b
- **DRUG:** interferon alfa-2b
- **DRUG:** interferon alfa-2b

## Key facts

- **NCT ID:** NCT00624325
- **Lead sponsor:** Foundation for Liver Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624325, "Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00624325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*